Welcome to the new PharmaVoice.
As Industry Dive relaunches PharmaVoice, our new digital format will carry forward and build on the publication’s important legacy in the industry. The site may look different but our mission remains the same: to provide a forum for thought leadership and tell the stories of the people and organizations who make important breakthroughs in the life sciences.
Now with a convenient daily email newsletter (sign up here!) and a beautiful, redesigned website, PharmaVoice will continue to be the leading community for life sciences leaders to share their stories, voices and ideas and help move the industry forward. You will find interviews with newsmakers, profiles of people and organizations leading change, opinions from industry leaders, in-depth articles on important trends and issues, and much more.
Our first several stories include a look at 5 trends shaping clinical trial regulations, a discussion of how pharma companies are tackling the talent crunch, and an interview with Ovid CEO Jeremy Levin on rare disease drug development. (You can also find all 20 years of archived PharmaVoice content, including PDFs of old magazine issues and our PharmaVoice 100 lists, on the new site if you search for them.)
We are excited to build on the community that you have come to know and rely on over the years.
Taren Grom, the founder and longtime Editor-in-Chief of PharmaVoice, will be joining us as Editor-in-Chief Emeritus, where she will be regularly interviewing leaders in the space and leading the Woman of the Week podcast series, the PharmaVOICE 100 annual list and event, and future virtual events we plan to offer. Robin Robinson, the longtime Sr. Editor of the publication, is expanding her role as the Lead Editor for the new PharmaVoice and will work closely with our writers to shape stories and deliver the daily newsletter. Meagan Parrish, who was previously the Sr. Editor for Pharma Manufacturing magazine, joins us as Sr. Editor & Writer and will interview leaders and write profiles, case studies, features and more. Kim Ribbink will continue to work closely with the publication and provide stories.
If you want to read more about the editorial team or learn how to best reach out to them, you can visit our team page.
Join our next chapter by signing up for our daily email newsletter, and please reach out to us at [email protected] if you have any feedback, contributions, ideas, questions or anything else you want to share with our team. Read, think, participate…and stay tuned for our first newsletter issue on Tuesday, January 18.
